PMID- 32858970
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240329
IS  - 2076-3921 (Print)
IS  - 2076-3921 (Electronic)
IS  - 2076-3921 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Aug 26
TI  - Nitric Oxide Nano-Delivery Systems for Cancer Therapeutics: Advances and 
      Challenges.
LID - 10.3390/antiox9090791 [doi]
LID - 791
AB  - Nitric oxide (NO) plays important roles in various physiological and pathological 
      functions and processes in the human body. Therapeutic application of NO 
      molecules has been investigated in various diseases, including cardiovascular 
      disease, cancer, and infections. However, the extremely short half-life of NO, 
      which limits its clinical use considerably, along with non-specific distribution, 
      has resulted in a low therapeutic index and undesired adverse effects. To 
      overcome the drawbacks of using this gaseous signaling molecule, researchers in 
      the last several decades have focused on innovative medical technologies, 
      specifically nanoparticle-based drug delivery systems (DDSs), because these 
      systems alter the biodistribution of the therapeutic agent through controlled 
      release at the target tissues, resulting in a significant therapeutic drug 
      effect. Thus, the application of nano-systems for NO delivery in the field of 
      biomedicine, particularly in the development of new drugs for cancer treatment, 
      has been increasing worldwide. In this review, we discuss NO delivery 
      nanoparticle systems, with the aim of improving drug delivery development for 
      conventional chemotherapies and controlling multidrug resistance in cancer 
      treatments.
FAU - Vong, Long Binh
AU  - Vong LB
AD  - School of Biomedical Engineering, International University, Ho Chi Minh 700000, 
      Vietnam.
AD  - Vietnam National University Ho Chi Minh City (VNU-HCM), Ho Chi Minh 700000, 
      Vietnam.
FAU - Nagasaki, Yukio
AU  - Nagasaki Y
AUID- ORCID: 0000-0001-7975-6510
AD  - Department of Materials Science, Graduate School of Pure and Applied Sciences, 
      University of Tsukuba, Tsukuba, Ibaraki 305-8573, Japan.
AD  - Master's School of Medical Sciences, Graduate School of Comprehensive Human 
      Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan.
AD  - Center for Research in Isotopes and Environmental Dynamics (CRiED), University of 
      Tsukuba, Tennoudai 1-1-1, Tsukuba, Ibaraki 305-8573, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200826
PL  - Switzerland
TA  - Antioxidants (Basel)
JT  - Antioxidants (Basel, Switzerland)
JID - 101668981
PMC - PMC7555477
OTO - NOTNLM
OT  - angiogenesis
OT  - cancer
OT  - drug resistance
OT  - gaseous signaling molecule
OT  - nitric oxide
OT  - self-assembled nanomedicine
COIS- The authors declare no conflict of interest.
EDAT- 2020/08/30 06:00
MHDA- 2020/08/30 06:01
PMCR- 2020/08/26
CRDT- 2020/08/30 06:00
PHST- 2020/07/31 00:00 [received]
PHST- 2020/08/21 00:00 [revised]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/08/30 06:00 [entrez]
PHST- 2020/08/30 06:00 [pubmed]
PHST- 2020/08/30 06:01 [medline]
PHST- 2020/08/26 00:00 [pmc-release]
AID - antiox9090791 [pii]
AID - antioxidants-09-00791 [pii]
AID - 10.3390/antiox9090791 [doi]
PST - epublish
SO  - Antioxidants (Basel). 2020 Aug 26;9(9):791. doi: 10.3390/antiox9090791.